Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229–63.

PubMed  Google Scholar 

Saleh Y, Abu Hejleh T, Abdelrahim M, Shamseddine A, Chehade L, Alawabdeh T, et al. Hepatocellular carcinoma: the evolving role of systemic therapies as a bridging treatment to liver transplantation. Cancers. 2024;16:2081.

CAS  PubMed  PubMed Central  Google Scholar 

Zarlashat Y, Abbas S, Ghaffar A. Hepatocellular carcinoma: beyond the border of advanced stage therapy. Cancers. 2024;16:2034.

CAS  PubMed  PubMed Central  Google Scholar 

Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–905.

CAS  PubMed  Google Scholar 

Abou-Alfa GK, Lau G, Kudo M, Chan SL, Kelley RK, Furuse J, et al. Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evid. 2022;1:EVIDoa2100070.

PubMed  Google Scholar 

Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline update. J Clin Oncol. 2024;42:1830–50.

CAS  PubMed  Google Scholar 

Arvanitakis K, Koletsa T, Mitroulis I, Germanidis G. Tumor-associated macrophages in hepatocellular carcinoma pathogenesis, prognosis and therapy. Cancers. 2022;14:226.

CAS  PubMed  PubMed Central  Google Scholar 

Lopez-Yrigoyen M, Cassetta L, Pollard JW. Macrophage targeting in cancer. Ann N Y Acad Sci. 2021;1499:18–41.

PubMed  Google Scholar 

Wang PC, Hu ZQ, Zhou SL, Yu SY, Mao L, Su S, et al. The spatial distribution of immune cell subpopulations in hepatocellular carcinoma. Cancer Sci. 2022;113:423–31.

CAS  PubMed  Google Scholar 

Sheng J, Zhang J, Wang L, Tano V, Tang J, Wang X, et al. Topological analysis of hepatocellular carcinoma tumour microenvironment based on imaging mass cytometry reveals cellular neighbourhood regulated reversely by macrophages with different ontogeny. Gut. 2022;71:1176–91.

CAS  PubMed  Google Scholar 

Zhou C, Weng J, Liu C, Liu S, Hu Z, Xie X, et al. Disruption of SLFN11 deficiency-induced CCL2 signaling and macrophage M2 polarization potentiates anti-PD-1 therapy efficacy in hepatocellular carcinoma. Gastroenterology. 2023;164:1261–78.

CAS  PubMed  Google Scholar 

Li X, Yao W, Yuan Y, Chen P, Li B, Li J, et al. Targeting of tumour-infiltrating macrophages via CCL2/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma. Gut. 2017;66:157–67.

CAS  PubMed  Google Scholar 

Han S, Bao X, Zou Y, Wang L, Li Y, Yang L, et al. d-lactate modulates M2 tumor-associated macrophages and remodels immunosuppressive tumor microenvironment for hepatocellular carcinoma. Sci Adv. 2023;9:eadg2697.

CAS  PubMed  PubMed Central  Google Scholar 

Lee TK, Castilho A, Cheung VC, Tang KH, Ma S, Ng IO. CD24(+) liver tumor-initiating cells drive self-renewal and tumor initiation through STAT3-mediated NANOG regulation. Cell Stem Cell. 2011;9:50–63.

CAS  PubMed  Google Scholar 

Liu AY, Cai Y, Mao Y, Lin Y, Zheng H, Wu T, et al. Twist2 promotes self-renewal of liver cancer stem-like cells by regulating CD24. Carcinogenesis. 2014;35:537–45.

CAS  PubMed  Google Scholar 

Tsuchiya H, Shiota G. Clinical and biological implications of cancer stem cells in hepatocellular carcinoma. Yonago Acta Med. 2021;64:1–11.

CAS  PubMed  PubMed Central  Google Scholar 

Tsuchiya H, Shiota G. Immune evasion by cancer stem cells. Regen Ther. 2021;17:20–33.

CAS  PubMed  PubMed Central  Google Scholar 

Barkal AA, Brewer RE, Markovic M, Kowarsky M, Barkal SA, Zaro BW, et al. CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy. Nature. 2019;572:392–6.

CAS  PubMed  PubMed Central  Google Scholar 

Chen GY, Tang J, Zheng P, Liu Y. CD24 and Siglec-10 selectively repress tissue damage-induced immune responses. Science. 2009;323:1722–5.

CAS  PubMed  PubMed Central  Google Scholar 

Li X, Tian W, Jiang Z, Song Y, Leng X, Yu J. Targeting CD24/Siglec-10 signal pathway for cancer immunotherapy: recent advances and future directions. Cancer Immunol Immunother. 2024;73:31.

CAS  PubMed  PubMed Central  Google Scholar 

Koyama S, Tsuchiya H, Amisaki M, Sakaguchi H, Honjo S, Fujiwara Y, et al. NEAT1 is required for the expression of the liver cancer stem cell marker CD44. Int J Mol Sci. 2020;21:1927.

CAS  PubMed  PubMed Central  Google Scholar 

Sakaguchi H, Tsuchiya H, Kitagawa Y, Tanino T, Yoshida K, Uchida N, et al. NEAT1 confers radioresistance to hepatocellular carcinoma cells by inducing autophagy through GABARAP. Int J Mol Sci. 2022;23:711.

CAS  PubMed  PubMed Central  Google Scholar 

Tsuchiya H, Shinonaga R, Sakaguchi H, Kitagawa Y, Yoshida K, Shiota G. NEAT1 confers radioresistance to hepatocellular carcinoma cells by inducing PINK1/Parkin-mediated mitophagy. Int J Mol Sci. 2022;23:14397.

CAS  PubMed  PubMed Central  Google Scholar 

Tsuchiya H, Shinonaga R, Sakaguchi H, Kitagawa Y, Yoshida K. NEAT1-SOD2 axis confers sorafenib and lenvatinib resistance by activating AKT in liver cancer cell lines. Curr Issues Mol Biol. 2023;45:1073–85.

CAS  PubMed  PubMed Central  Google Scholar 

Yin L, Wang Y. Extracellular vesicles derived from M2-polarized tumor-associated macrophages promote immune escape in ovarian cancer through NEAT1/miR-101-3p/ZEB1/PD-L1 axis. Cancer Immunol Immunother. 2023;72:743–58.

CAS  PubMed  Google Scholar 

Heideveld E, Horcas-Lopez M, Lopez-Yrigoyen M, Forrester LM, Cassetta L, Pollard JW. Methods for macrophage differentiation and in vitro generation of human tumor associated-like macrophages. Methods Enzymol. 2020;632:131.

Google Scholar 

Yuan W, Zhang Q, Gu D, Lu C, Dixit D, Gimple RC, et al. Dual role of CXCL8 in maintaining the mesenchymal state of glioblastoma stem cells and M2-like tumor-associated macrophages. Clin Cancer Res. 2023;29:3779–92.

CAS  PubMed  Google Scholar 

Tsai SC, Lin CC, Shih TC, Tseng RJ, Yu MC, Lin YJ, et al. The miR-200b-ZEB1 circuit regulates diverse stemness of human hepatocellular carcinoma. Mol Carcinog. 2017;56:2035–47.

CAS  PubMed  Google Scholar 

Thomas S, Harding MA, Smith SC, Overdevest JB, Nitz MD, Frierson HF, et al. CD24 is an effector of HIF-1-driven primary tumor growth and metastasis. Cancer Res. 2012;72:5600–12.

CAS  PubMed  PubMed Central  Google Scholar 

Yu W, Ma Y, Shankar S, Srivastava RK. Role of SATB2 in human pancreatic cancer: implications in transformation and a promising biomarker. Oncotarget. 2016;7:57783–97.

PubMed  PubMed Central  Google Scholar 

Chen J, Li H, Zhang B, Xiong Z, Jin Z, Chen J, et al. ABI2-mediated MEOX2/KLF4-NANOG axis promotes liver cancer stem cell and drives tumour recurrence. Liver Int. 2022;42:2562–76.

CAS  PubMed  PubMed Central  Google Scholar 

Lin CY, Tsai CL, Chao A, Lee LY, Chen WC, Tang YH, et al. Nucleophosmin/B23 promotes endometrial cancer cell escape from macrophage phagocytosis by increasing CD24 expression. J Mol Med. 2021;99:1125–37.

CAS  PubMed  Google Scholar 

Agarwal N, Dancik GM, Goodspeed A, Costello JC, Owens C, Duex JE, et al. GON4L drives cancer growth through a YY1-androgen receptor-CD24 axis. Cancer Res. 2016;76:5175–85.

CAS  PubMed  PubMed Central  Google Scholar 

Rauluseviciute I, Riudavets-Puig R, Blanc-Mathieu R, Castro-Mondragon JA, Ferenc K, Kumar V, et al. JASPAR 2024: 20th anniversary of the open-access database of transcription factor binding profiles. Nucleic Acids Res. 2024;52:D174–D182.

CAS  PubMed  Google Scholar 

Saleh RO, Alkhafaji AT, Mohammed JS, Bansal P, Kaur H, Ahmad I, et al. LncRNA NEAT1 in the pathogenesis of liver-related diseases. Cell Biochem Funct. 2024;42:e4006.

CAS  PubMed  Google Scholar 

Zhang Y, Huang C, Zhu Z, Hou Y, Huang S, Sun C, et al. lncRNA NEAT1 regulates the proliferation and migration of hepatocellular carcinoma cells by acting as a miR‑320a molecular sponge and targeting L antigen family member 3. Int J Oncol. 2020;57:1001–12.